Quick answers for GLP‑1 in Australia
- What they are: GLP‑1 receptor agonists support appetite control and glucose regulation; tirzepatide is GLP‑1/GIP dual‑agonist.
- Approved brands: Ozempic, Wegovy, Rybelsus (semaglutide); Mounjaro and Zepbound (tirzepatide); Trulicity (dulaglutide); Saxenda (liraglutide).
- Indications: Type 2 diabetes (T2D) and/or chronic weight management, depending on the brand.
- PBS: Generally for T2D indications under set criteria. Weight‑management indications are not PBS‑subsidised.
- Access: Prescription‑only via GP, specialist or telehealth. Beware non‑prescription “research” or imported products.
- Common effects: Nausea, reflux, diarrhoea or constipation during dose escalation; dose titration helps tolerance.
How GLP‑1 and dual‑agonist medicines work
GLP‑1 receptor agonists mimic the gut hormone GLP‑1 to increase fullness, reduce appetite, slow gastric emptying and stimulate glucose‑dependent insulin release while suppressing glucagon. Tirzepatide also activates the GIP receptor, which can further enhance metabolic effects in some people.
- Appetite and satiety: Earlier fullness and lower hunger between meals.
- Gastric emptying: Slower stomach emptying can reduce portion sizes.
- Glycaemic control: More insulin when glucose is high and less glucagon.
Effects build gradually with dose titration and lifestyle support (adequate protein, fibre and hydration).
Approved GLP‑1 and dual‑agonist brands in Australia
The following brands are TGA‑approved. Availability can vary with supply. Always confirm current indications and Product Information.
- Semaglutide
- Ozempic: T2D treatment. Prescription‑only; PBS applies to eligible T2D criteria.
- Wegovy: Chronic weight management for eligible adults; private prescription (not PBS).
- Rybelsus (oral): T2D treatment; prescription‑only. Check PBS for current status and criteria.
- Tirzepatide
- Mounjaro: T2D treatment. Prescription‑only; PBS criteria may apply for eligible T2D.
- Zepbound: Chronic weight management for eligible adults; private prescription (not PBS).
- Other GLP‑1s
- Trulicity (dulaglutide): T2D treatment; PBS criteria apply for eligible T2D.
- Saxenda (liraglutide): Chronic weight management; private prescription (not PBS).
For brand‑specific details, see: Ozempic Australia, Wegovy Australia, Mounjaro Australia, Rybelsus Australia, Trulicity Australia, Saxenda Australia.
Who may be eligible and how access works
GLP‑1 and dual‑agonist therapies are Schedule 4 medicines. You need a prescription from a GP, endocrinologist or authorised telehealth provider. Typical steps:
- Clinical assessment: Medical history, medications, weight/BMI, comorbidities and contraindications.
- Indication check: T2D vs chronic weight management and brand fit.
- Baseline measures: Weight, waist, HbA1c or fasting glucose (for diabetes), lipids and blood pressure as appropriate.
- Plan and monitoring: Dose titration, side‑effect management, follow‑ups and lifestyle support.
Weight‑management indications commonly reference adults with BMI ≥30, or ≥27 with at least one weight‑related condition (for example, hypertension, dyslipidaemia or obstructive sleep apnoea). Your clinician will confirm the current TGA indication and your suitability.
Dosing overview and titration principles
Dosing is brand‑specific and must follow the Product Information. In general, clinicians start low and increase gradually to improve tolerability.
- Semaglutide (injectable): Often starts at 0.25 mg once weekly, stepping up over weeks.
- Tirzepatide: Often starts at 2.5 mg once weekly, with stepwise increases.
- Liraglutide (Saxenda): Daily injection with weekly step‑ups.
Missed‑dose and switching rules vary; do not change your dose without medical advice.
Side effects, interactions and key warnings
Common effects (often transient during titration): nausea, vomiting, diarrhoea or constipation, reflux/heartburn, reduced appetite, fatigue, and injection‑site reactions. Eating slowly, smaller portions, adequate hydration and protein can help.
Serious risks and warnings—seek medical advice urgently for:
- Severe or persistent abdominal pain (possible pancreatitis).
- Symptoms of gallbladder disease (upper right abdominal pain, fever, jaundice).
- Signs of dehydration or acute kidney injury (very reduced urine, dizziness, confusion).
- Allergic reactions (swelling, difficulty breathing).
Contraindications and cautions can include: personal/family history of medullary thyroid carcinoma or MEN2, pregnancy, breastfeeding, prior pancreatitis, severe GI disease, and interactions that raise hypoglycaemia risk when used with insulin or sulfonylureas.
Costs, PBS snapshot and supply considerations
- PBS: Generally applies to eligible type 2 diabetes indications with specific criteria. Weight‑management indications are privately funded.
- Private costs: Vary by brand, dose and pharmacy; consult our brand pages for current ranges: Semaglutide cost, Tirzepatide cost, Wegovy cost, Mounjaro cost, Ozempic cost.
- Supply: Periodic shortages have occurred. Your prescriber or pharmacist can advise on brand availability and safe switching where appropriate.
Shortages, switching and expectations
Supply constraints can affect starting dose pens or higher strengths. If a product is unavailable, do not buy unapproved substitutes. Ask your prescriber about:
- Waiting for supply vs switching to an approved alternative.
- Re‑titration if you have a gap in treatment.
- Monitoring plans when changing brand or dose.
Expect weight to plateaus over time; sustainable habits improve long‑term outcomes and help limit regain if therapy stops.
Legal access, compounding and import risks in Australia
GLP‑1 and dual‑agonist products are prescription‑only Schedule 4 medicines. Buying “research” versions, grey‑market imports or counterfeit pens is unlawful and risky. Compounded GLP‑1 products face strict TGA controls and are only permissible in limited circumstances; many advertised variants (for example, “semaglutide sodium”) are not approved medicines.
- Personal Importation Scheme: Strict rules apply and a valid Australian prescription is required; unlawful imports may be seized.
- Counterfeits: Documented in online markets; incorrect dose strength, contamination and device failures are common red flags.
Learn more: Are Peptides Legal in Australia?, Semaglutide Prescription Australia, Tirzepatide Prescription Australia, Buy Semaglutide Australia, Buy Tirzepatide Australia.
Frequently asked questions
What does “GLP‑1 Australia” usually mean in searches?
People are typically looking for approved brands (Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, Saxenda), eligibility, PBS rules, costs and where to access legitimate prescriptions.
Ozempic vs Wegovy—what’s the difference?
Both contain semaglutide. Ozempic is indicated for T2D; Wegovy is for chronic weight management. Dosing and device strengths differ, and only diabetes indications have PBS subsidy.
Mounjaro vs Zepbound—how do they differ?
Both contain tirzepatide (dual GLP‑1/GIP). Mounjaro is for T2D; Zepbound is for chronic weight management. Subsidy applies to specific T2D criteria; weight management is private.
How fast do GLP‑1 medicines work?
Appetite changes can appear in the first few weeks at starter doses; weight and HbA1c outcomes are typically assessed over 3–6 months as doses are titrated.
Can I drink alcohol while on GLP‑1 therapy?
Alcohol can worsen nausea and affect glucose control. Discuss safe limits with your clinician, especially if you have diabetes or pancreatitis risk factors.
What if I’m planning pregnancy?
GLP‑1 and dual‑agonist medicines are not recommended during pregnancy or breastfeeding. You’ll need a pre‑conception plan with your clinician.
Can I switch between brands?
Sometimes, with medical supervision. Re‑titration and monitoring are often required. Do not switch products or doses without advice.
Will I regain weight if I stop?
Appetite often rebounds after stopping. A maintenance plan—nutrition, activity, sleep and behavioural support—helps reduce regain.
Where can I compare results and side effects?
See Semaglutide vs Tirzepatide Weight Loss and our brand pages for detailed comparisons.
Ask for GLP‑1 help
Have questions about eligibility, brand fit, PBS or side effects? Send your questions below and we’ll connect you with guidance tailored to the Australian system.
Prefer to read first? See our overview: Weight Loss Injections Australia.
Key takeaways
- GLP‑1 and dual‑agonist medicines are effective tools for T2D and weight management when prescribed and monitored properly.
- Australia has multiple approved brands; PBS applies to diabetes indications, not weight management.
- Start low and titrate; manage side effects proactively; avoid unapproved or imported products.
- Combine medication with nutrition, activity, sleep and follow‑up for sustainable results.